Progress in Neuroinflammation Mechanisms and Targeted Therapy of Tinnitus
Journal of Biosciences and Medicines · 2026 · 14 (06) · 332-344
DOI: 10.4236/jbm.2026.146022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biosciences and Medicines, 2026. Verfasst von Guoli Hu und 3 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tinnitus is a common auditory perception disorder, and its pathological mechanisms have not been fully elucidated. In recent years, neuroinflammation has garnered widespread attention as a new direction in the study of central mechanisms of tinnitus. This review systematically summarizes the roles of microglia and astrocytes, the TLR4/NF-κB/NLRP3 signaling axis, pro-inflammatory cytokines, and crosstalk between oxidative stress and inflammation in tinnitus. We highlight how neuroinflammation drives auditory central plasticity and remodeling, and discuss recent advances in anti-neuroinflammatory clinical interventions. Studies have shown that neuroinflammation plays a key role in the initiation and maintenance of tinnitus by affecting the neural plasticity of the auditory pathway and limbic system. Targeting neuroinflammation may provide new strategies for tinnitus treatment.
Zitieren
APA
Hu, G., Huang, Y., Wu, J., & Liu, J. (2026). Progress in Neuroinflammation Mechanisms and Targeted Therapy of Tinnitus. Journal of Biosciences and Medicines, 14(06), 332-344. https://doi.org/10.4236/jbm.2026.146022
Vancouver
Hu G, Huang Y, Wu J, Liu J. Progress in Neuroinflammation Mechanisms and Targeted Therapy of Tinnitus. Journal of Biosciences and Medicines. 2026;14(06):332-344. doi:10.4236/jbm.2026.146022
BibTeX
@article{Hu2026,
author = {Hu, Guoli and Huang, Yewen and Wu, Jiahui and Liu, Jin},
title = {Progress in Neuroinflammation Mechanisms and Targeted Therapy of Tinnitus},
journal = {Journal of Biosciences and Medicines},
year = {2026},
volume = {14},
number = {06},
pages = {332--344},
doi = {10.4236/jbm.2026.146022}
}
EUVIMED